Overview
Announcements

Ordinary Adjustment | Solactive China Healthcare Disruption Index | Effective Date 1st September 2025

Solactive China Healthcare Disruption Index:

In the ordinary adjustment, the following composition will be implemented effective open 1st September 2025:

ABBISKO CAYMAN LTD
AKESO INC
ALIBABA HEALTH INFORMATION TECHNOLOGY LTD
ALPHAMAB ONCOLOGY
ASCLETIS PHARMA INC
CHINA MEDICAL SYSTEM HOLDINGS LTD
CHINA RESOURCES PHARMACEUTICAL
CSPC PHARMACEUTICAL GROUP LTD
CSTONE PHARMACEUTICALS
EVEREST MEDICINES LTD
GENSCRIPT BIOTECH CORP
GRAND PHARMACEUTICAL GROUP LTD
HANSOH PHARMACEUTICAL GROUP CO
HBM HOLDINGS LTD
HENGRUI PHARMA ORD H
HUTCHMED CHINA LTD
IMMUNEONCO-B ORD H
INNOVENT BIOLOGICS INC
JACOBIO PHARMACEUTICALS GROUP CO LTD
JINHAI INTERNATIONAL GROUP HOLDINGS LTD
KANGJI MEDICAL HOLDINGS LTD
KEYMED BIOSCIENCES INC
LEPU BIOPHARMA CO LTD-H
LIVZON PHARMACEUTICAL GROUP INC
LUYE PHARMA GROUP LTD
MEDLIVE TECHNOLOGY CO LTD
PHARMARON BEIJING CO LTD-H
QUANTUMPHARM INC
QYUNS-B ORD H
REMEGEN CO LTD-H
SHANDONG BOAN BIOTECHNOLOGY CO LTD
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD
SHANGHAI FUDAN-ZHANGJIANG BIO-
SHANGHAI HENLIUS BIOTECH INC
SHANGHAI JUNSHI BIOSCIENCES CO LTD
SHANGHAI MICROPORT MEDBOT GR
SHANGHAI PHARMACEUTICALS HOLDING CO LTD-H
SIHUAN PHARMACEUTICAL HLDGS GRP ORD
SIMCERE PHARMACEUTICAL GROUP
SINO BIOPHARMACEUTICAL LTD ORD
SKB BIO-B ORD H
TYK MEDICINES-B ORD H
WUXI APPTEC CO LTD
WUXI BIOLOGICS CAYMAN INC
ZAI LAB LTD